Curr Treat Options in Rheum DOI 10.1007/s40674-020-00143-0 Vasculitis (L Barra, Section Editor) An Overview of Conventional and Recent Treatment Options for Behcet’s Disease Kader Cetin Gedik, MD Micol Romano, MD Roberta A. Berard, MD, MSc FRCPC Erkan Demirkaya, MD, MSc FRCPC * Address * Schulich School of Medicine & Dentistry, Department of Paediatrics, Division of Paediatric Rheumatology, University of Western Ontario, 800 Commissioners Rd E. B1-146, London, ON, N6A 5W9, Canada Email: Erkan.Demirkaya@lhsc.on.ca * Springer Nature Switzerland AG 2020 This article is part of the Topical Collection on Vasculitis Keywords Behcet’s disease I Treatment I Biologics I Neurological involvement I Gastrointestinal involvement I Behcet’s uveitis Abstract Purpose of review Behcet’s disease (BD) is a multi-system inflammatory disorder charac- terized by a relapsing–remitting course. Several treatment modalities with different mechanisms of action have been evaluated for the treatment of BD. In this review, our goal is to review updated therapeutic options for BD in the light of recently published The European League Against Rheumatism (EULAR) recommendations. Recent findings Behcet’s disease can be difficult to treat with conventional treatment requiring escalation of therapy. In recent years, treatment of BD has become more effective since the understanding of the pathogenesis led to the use of a wide spectrum of therapeutic agents. Data in biologics have substantially increased in BD with different organ involvements in the last decades and providing promising results, although randomized controlled trials are lacking. Summary Behcet’s disease can affect multi-organ system therefore treatment should be determined based on the clinical presentation and organ involvement. Since there is a lack of randomized controlled trials, treatment options are usually based on expert consensus, case reports/series, and retrospective/prospective studies. As the development of biologic agents continues, it seems likely that understanding of their efficacy and safety will improve which may lead to a change in the management strategy and clinical outcomes of BD.